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Abstract
Background: Postpartum hemorrhage remains the leading cause of maternal morbidity and mortality worldwide.
Few population-based studies have examined the epidemiology of massive transfusion for postpartum
hemorrhage. The aim of this study was to determine the incidence, management, and outcomes of women with
postpartum hemorrhage who required massive transfusion in the Netherlands between 2004 and 2006.
Methods: Data for all women from a gestational age of 20 weeks onwards who had postpartum hemorrhage
requiring eight or more red blood cell concentrates were obtained from a nationwide population-based cohort
study including all 98 hospitals with a maternity unit in the Netherlands.
Results: Three hundred twenty-seven women who had postpartum hemorrhage requiring massive transfusion
were identified (massive transfusion rate 91 per 100,000 deliveries (95% confidence interval: 81–101)). The median
blood loss was 4500 mL (interquartile range 3250–6000 mL) and the median number of red blood cell concentrates
transfused was 11 units (interquartile range 9–16 units). Among women receiving massive transfusion, the most
common cause of hemorrhage was uterine atony. Eighty-three women (25%) underwent hysterectomy, 227 (69%)
were admitted to an intensive care unit, and three women died (case fatality rate 0,9%).
Conclusion: The number of women in the Netherlands who had postpartum hemorrhage treated with massive
transfusion was relatively high compared to other comparable settings. Evidence-based uniform management
guidelines are necessary.
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Background
Around the globe, postpartum hemorrhage (PPH) con-
tinues to be a leading cause of both maternal morbidity
and mortality [1, 2]. In the Netherlands, PPH is defined
by at least 1000 mL blood loss within 24 h of giving
birth. There has been an increase in the incidence of
PPH among all births in the Netherlands from 4.1% in
2000 to 6.4% in 2013 [3]. Although case definitions of
PPH vary between countries, this rising incidence of
PPH is also evident in other high-income countries
[4–8]. An explanation for the increasing rates of PPH
remains unclear.
In high-income countries, pharmacological, mechan-
ical and surgical methods as well as radiological arterial
embolization are available to arrest heavy bleeding. In
case of life-threatening PPH, access to and use of suffi-
cient quantities of blood products for transfusion to
treat severe anemia and correct clotting disorder are
critical [9, 10]. Clinical benefit of blood transfusion in
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obstetric hemorrhage was demonstrated in a hypothet-
ical experimental study showing a 6.5-fold increase in
risk of maternal death had red blood cell concentrates
(RBCs) not been available, as is the case in many low-
income settings [11].
Little is known about the management and outcomes
of women who sustain PPH requiring massive transfu-
sion. A recent population-based study from the United
Kingdom (UK) indicated that PPH requiring massive
transfusion was associated with high rates of morbidity
and hysterectomy [12]. While the rate of obstetric transfu-
sion in the Netherlands has decreased dramatically over
time (from 23% in 2000 to 3.9% in 2013), transfusion rates
in other high-income countries increased [3, 13, 14]. If
rates of massive transfusion in the Netherlands were to
have decreased over time, these data would be important
for informing discussion about best transfusion practices
for PPH management. The objective of our present study
was to determine incidence, causes, management and clin-
ical outcome of women with PPH requiring massive trans-
fusion in the Netherlands.
Methods
To determine incidence, causes, management approaches,
and clinical outcomes of women who had PPH requiring
massive transfusion in the Netherlands, we performed
a secondary analysis of data from the LEMMoN study
(Landelijke studie naar Etnische determinanten van
Maternale Morbiditeit in Nederland) [15].
The LEMMoN study included 358,874 deliveries with
severe acute maternal morbidity that occurred in 98 hos-
pitals with a maternity unit in the Netherlands (100%)
between 1st August 2004 and 1st August 2006. Severe
acute maternal morbidity was categorized into five
groups: intensive care unit (ICU) admission, uterine
rupture, eclampsia/HELLP syndrome, major obstetric
hemorrhage and a miscellaneous group. Major obstetric
hemorrhage was defined as a need for transfusion of
four or more units of erythrocyte concentrate or
embolization or hysterectomy following PPH. Detailed
information about study design and data collection were
described previously [15]. For this specific study, we
selected women from the LEMMoN cohort who were
classified as ‘major obstetric hemorrhage’, had a gesta-
tional age of at least 20 weeks and received massive
transfusion, defined as eight or more red blood cell
concentrates within the first 24 h after delivery.
We recorded maternal characteristics (age, body mass
index (BMI), geographical ethnic origin (the Netherlands,
other European Countries or non-Western immigrants,
subdivided into Middle East/North Africa, sub-Saharan
Africa, South America and Far East), parity, previous
experienced PPH and previous cesarean section), preg-
nancy characteristics (gestational age, mode of delivery,
induction of labour, multiple pregnancy and preeclampsia)
and specific data on postpartum hemorrhage (amount of
blood loss, number of red blood cell concentrates trans-
fused, hemoglobin levels at onset of bleeding, after bleed-
ing and at day of discharge). Maternal and pregnancy
characteristics of women in this study were compared to
the general pregnant population of the Netherlands, ob-
tained from Statistics Netherlands (CBS) and National
Perinatal Database (LVR-2). Incidence figures in LVR-2
were multiplied by 59/100 to also represent all deliveries
under primary care (41% in 2002) [16, 17].
Since postpartum hemorrhage is often the result of con-
current causes, we re-examined all cases of massive trans-
fusion within the LEMMoN-cohort and registered up to
three causes of PPH requiring massive transfusion for
each individual case. Only those causes that contributed
significantly to the hemorrhage were registered. These
causes were noted as uterine atony, uterine rupture, ia-
trogenic during/after cesarean section, placental abnor-
malities (including retained placenta, placental remnant,
placenta previa, abnormally invasive placenta and placen-
tal abruption (resulting in continuous hemorrhage in the
postpartum period), laceration of vagina and/or cervix,
primary clotting disorder with or without amniotic fluid
embolism, rupture of the uterine artery, rupture of the
liver capsule and uterine inversion. Causes of hemorrhage
were analyzed by mode of birth (spontaneous vaginal de-
livery, instrumental vaginal delivery, elective cesarean
section, emergency cesarean section and termination of
pregnancy) and number of red blood cell concentrates
transfused (‘moderate’ (8–12 units), ‘high’ (13–20 units)
and ‘immense’ (>20 units). The cut-off points for the
number of red blood cell concentrates transfused were
identical to those described by Green et al. [12].
Management of postpartum hemorrhage requiring
massive transfusion was divided into uterotonic agents
(oxytocin, prostaglandin F2α, ergometrine, misoprostol),
non-uterotonic drugs (tranexamic acid), mechanical in-
terventions (intrauterine balloon, intrauterine packing
and intra-abdominal packing), surgical interventions
(removal of the placenta not performed during cesarean
section, laparotomy, re-laparotomy, B-Lynch suture,
uterine artery ligation and hysterectomy) and uterine
artery embolization. Outcome of women was determined
by need for hysterectomy, length of hospitalization, ICU ad-
mission, morbidity, maternal deaths and case fatality rate.
Statistical analyses were performed using IBM SPSS
Statistics (version 22.0; SPSS Inc., Chicago, IL). Discrete
data were summarized as frequencies and percentages,
while continuous data were noted as medians with an
interquartile range (IQR) expressed as the 25th and 75th
percentiles. Women with a missing value for a specific
parameter were excluded when calculating the rate for
that variable.
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Results
During the study period, 358,874 deliveries took place in
the Netherlands; 336 women sustained PPH and were
given eight or more units of red blood cell concentrates.
Of these women, nine were excluded due to a gestational
age below 20 weeks, leaving 327 women for analysis. Inci-
dence of massive transfusion due to PPH was 91 per
100,000 deliveries (95% confidence interval [95% CI]: 81–
101). Clinical and demographic baseline characteristics for
women are presented in Table 1 and characteristics of the
pregnancies in Table 2. The median (IQR) age, BMI and
gestational age were 33 years (30–36 years), 23 kg/m2
(21–26 kg/m2) and 38 weeks (37–41 weeks), respectively.
Characteristics of postpartum hemorrhage requiring
massive transfusion
The median (IQR) estimated blood loss was 4500 mL
(3250–6000 mL), resulting in a median (IQR) hemoglobin
drop from 11.6 g/dL (10.8–12.41 g/dL; data missing for 60
women) before hemorrhage to 5.96 g/dL (5–6.77 g/dL;
data missing for 34 women) after hemorrhage. The
median (IQR, range) number of red blood cell con-
centrates transfused was 11 (9–16, 8–52) (see Additional
file 1 for distribution).
The most common cause of PPH requiring massive
transfusion was uterine atony, followed by retained
placenta and placenta previa (Table 3). For 117 women
(36%), two causes were registered and for 12 women
(4%) three. The commonest combinations for women
with two causes were uterine atony with retained pla-
centa (N = 28), uterine atony with placental remnant
(N = 21) and uterine atony with cervical laceration
(N = 10). For women with three causes, the most fre-
quent combination was uterine atony with placental
remnant and cervical laceration (N = 3). For nine
women, no cause could be established. The 22 causes in
the ‘other’ category in Table 3 were primary clotting
disorder without amniotic fluid embolism (N = 7), uterine
artery rupture (N = 6), live capsule rupture (N = 4), clot-
ting disorder due to amniotic fluid embolism (N = 4) and
uterine inversion (N = 1). Massive transfusion occurred
during normal working hours (between 0800 and 1600 on
a weekday) for 196 (65%) women; data were missing for
25 women. The onset of hemorrhage occurred at home
for 52 (16%) women; data were missing for 7 women.
Table 1 Characteristics of the women




20–34 208 (63) (75.3)
35–39 94 (29) (21.3)
≥ 40 25 (8) (3.4)
BMI (kg/m2)
< 18,5 15 (5) (3.1)
18,5–24,9 137 (42) (65.2)
25,0–29,9 39 (12) (21.9)
≥ 30 24 (7) (9.8)
Unknown 112 (34) –
Geographical ethnic origin
The Netherlands 223 (68) N/A
Other European Countries 7 (2) N/A
Non-Western immigrants; 70 (22) (16.8)
Middle East/North Africa 28 (7) N/A
Sub-Saharan Africa 17 (5) N/A
South America 16 (5) N/A
Far East 9 (3) N/A
Unknown 27 (8) –
Parity
0 158 (48.3) (45.2)
1–2 145 (44.3) (49.8)
≥ 3 24 (7.3) (5.0)
Previous postpartum hemorrhage 40 (12) N/A
Previous cesarean section 66 (20) (6.0)
N/A data not available
aNational reference values from Statistics Netherlands (exact study period) [16]
Table 2 Characteristics of pregnancy and birth




Preterm (<37 weeks); 86 (26) (5.8)b
20–24 weeks 6 (2) N/A
24–32 weeks 18 (5) N/A
32–37 weeks 62 (19) N/A
Full Term 241 (74) (94.2)b
Mode of delivery c
Vaginal 131 (40) (78.4)b
Instrumental 43 (13) (8.6)b
Cesarean Section; 151 (46) (13.0)b
Elective 46 (14) N/A
Emergency 105 (32) N/A
Induction of labour 100 (31) (12.5)b
Multiple pregnancy 37 (11) (1.7)a
Preeclampsia during pregnancy 54 (17) (4) [19]
N/A data not available
aNational reference values from Statistics Netherlands (exact study period) [16]
bNational reference values from the Netherlands Perinatal Registry (LVR-2,
2005) [17]
cIn case of multiple births were the mode of delivery differed between the
neonates, the mode of delivery refers to the most invasive mode
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Table 4 presents the top three causes of postpartum
hemorrhage requiring eight or more units of red blood
cells according to mode of birth. The commonest cause
during elective cesarean section was placenta previa
(52%, N = 24/46), whereas uterine atony remained the
leading cause for the other modes of delivery. Categoriz-
ing causes of PPH by number of red blood cell concen-
trates transfused, respectively ‘moderate’ (N = 193), ‘high
(N = 89) and ‘immense’ (N = 39), showed no difference
in prevalence of causes; uterine atony continued to be
the main cause in each group.
Management of postpartum hemorrhage requiring
massive transfusion
Oxytocin (84%) was the most frequently administered
uterotonic agent (prophylactic oxytocin excluded), followed
by prostaglandin F2α (70%) and ergometrine (18%)
(Table 5). No data regarding which uterotonic agent
was administered as first line treatment were retriev-
able, but of 284 women who received oxytocin, 210
(74%) were given prostaglandin F2α thereafter. Eleven
women who had uterine atony received no oxytocin.
Instead, these women received prostaglandin F2α and
one woman was supplemented with tranexamic acid.
Laparotomy was performed following 42/174 (24%)
vaginal deliveries and 82/151 (54%) cesarean sections. Re-
laparotomy was necessary in 10/42 (24%) and 20/82 (24%)
respectively. Of all 327 women, 83 (25%) underwent hys-
terectomy to control bleeding with highest rates in women
who sustained uterine rupture (N = 14/20, 70%) or any
form of abnormal placentation (N = 21/32, 66%).
Outcome of women requiring massive transfusion
The median (IQR) length of hospitalization was 9 days (6–
13 days; data missing for 14 women) and 227 women (69%)
required ICU admission. The median (IQR) hemoglobin on
the day of discharge was 10.15 g/dL (9.02–11.44 g/dL; data
missing for 53 women). One-hundred-and-twenty-one
(37%) women experienced some kind of morbidity, of
whom 40 (33%) developed respiratory failure and 13
(11%) experienced renal insufficiency. Other complica-
tions were paralytic ileus (N = 11), heart failure (N = 7),
Sheehan syndrome (N = 6) and cerebral venous sinus
thrombosis (N = 2). Maternal death occurred in three
women due to hypovolemic shock, ventricular fibrillation
and massive pulmonary embolism; case fatality rate of
postpartum hemorrhage requiring massive transfusion
was 1 in 109 (0,9%).
Discussion
Between 2004 and 2006, the incidence of postpartum
hemorrhage treated with massive transfusion was not-
ably high in the Netherlands (91 per 100,000 deliver-
ies). This is four times the incidence reported for the
United Kingdom between 2012 and 2013 (23 per
100,000 deliveries), and one-and-a-half times the inci-
dence reported for the state of New York between
1998 and 2007 (60 per 100,000 deliveries) [12, 18].
We found that the leading cause of PPH with massive
transfusion was uterine atony. One quarter of all
women receiving massive transfusion underwent hys-
terectomy to control bleeding.
Table 3 Causes of PPH cases requiring massive transfusiona
N (%)
Uterine atony 179 (55)
Placenta abnormalities; 173 (53)
Retained 54 (17)
Previa 37 (11)






Uterine rupture 20 (6)
Iatrogenic during/after cesarean 11 (3)
Other 22 (7)
Unknown 9 (3)
aUp to three causes per case could be included
Table 4 Top 3 causes categorized by mode of birtha
N (%)
Vaginal birth (N = 131)
1. Uterine atony 84 (64)
2. Retained placenta 40 (31)
3. Placental remnant 20 (15)
Instrumental vaginal birth (N = 43)
1. Uterine atony 26 (60)
2. Retained placenta 14 (33)
3. Placental remnant 6 (14)
Elective cesarean section (N = 46)
1. Placenta previa 24 (52)
2. Uterine atony 17 (37)
3. Abnormally invasive placenta 13 (28)
Emergency cesarean section (N = 105)
1. Uterine atony 51 (49)
2. Uterine rupture 13 (12)
3. Iatrogenic during/after cesarean 9 (9)
Termination of pregnancy (n = 2)
1. Uterine atony 1 (50)
2. Uterine rupture 1 (50)
aUp to three causes could be included
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The difference in the incidence of massive transfu-
sion due to PPH between the Netherlands and the
UK is remarkable. Whereas incidence of major obstet-
ric hemorrhage has differed between various countries
as a result of varying inclusion criteria [15, 19, 20],
our study applied the same inclusion criteria for
massive transfusion described by Green et al. [12]
The difference in incidence between the Netherlands
and the state of New York is also of note, particularly
since Mhyre et al. [18] used a higher threshold for
the number of red blood cell concentrates transfused
to define massive transfusion (≥10 units) and included
both antepartum and postpartum hemorrhage.
A distinct difference between the national guidelines
for the management of PPH between the Netherlands
(Dutch Society of Obstetrics and Gynaecology (NVOG))
and the United Kingdom (Royal College of Obstetricians
and Gynaecology (RCOG)) is that the RCOG specifically
recommends that ‘surgical interventions should be initi-
ated sooner rather than later’. Both guidelines are incon-
clusive concerning the administration of blood products;
NVOG (see Additional file 2 for a summary of the
NVOG PPH guideline represented as a chart [9]) recom-
mends not to deviate from the local guidelines of the
hospital, while RCOG states that the decision to provide
blood transfusion ‘should be based on both clinical and
hematological assessment’ [9, 10, 21]. Furthermore, it is
noteworthy that the median estimated blood loss in the
study from Green et al. was 6 L (4.5–8.0 L) versus 4.5 L
(3.3–6 L) in our cohort, whilst the massive transfusion
rate was four times higher in the Netherlands [12]. This
may suggest that the difference in transfusion rate is due
to differences in transfusion policy, which would emphasize
the need for uniform guidelines [22].
During the study period, there were 358,874 deliveries
in the Netherlands and 145,703 deliveries (40.6%) were
under the responsibility of a primary care giver, making
the risk of massive transfusion due to PPH 13 per
100.000 deliveries in midwifery care. Comparison of
women requiring massive transfusion due to PPH with
the general pregnant population in the Netherlands
showed that women requiring massive transfusion had a
multiple pregnancy in 11% of all cases versus 1.7% in the
general population [16], suffered from preeclampsia in
17% of all cases versus 4% in the general population
[23], had labour induced in 31% of all cases versus 12.5%
in the general population [17], had a preterm delivery
in 26% of all cases versus 5.8% in the general popula-
tion [17] and delivered by cesarean section in 46% in
all cases versus 13% in the general population [17].
These characteristics are known risk factors of PPH
and highlight that the management of postpartum
hemorrhage should not only be focused on treatment,
but on prevention as well [24, 25].
Uterine atony was the most frequent cause of post-
partum hemorrhage as is consistent with the literature
[12, 26, 27]. Atony was also the commonest cause of
PPH in home deliveries [28]. In elective cesarean sec-
tions the leading cause of massive transfusion due to
PPH was placenta previa. Green et al. reported placenta
accreta as the most frequent cause of PPH in women de-
livering by elective cesarean section, while Dupont et al.
Table 5 Distribution of obstetric interventions by cause; expressed as percentages
Atony Rupture Previa AIPa Abruption Retained Total
(N = 179) (N = 20) (N = 37) (N = 32) (N = 20) (N = 54) (N = 327)
Oxytocin 94 70 87 91 70 87 84
Prostaglandin F2α 87 50 54 72 55 85 70
Tranexamic acid 33 5 19 13 5 19 22
Ergometrine 23 15 14 19 20 28 18
Misoprostol 16 5 3 3 20 6 11
Removal of placentab 31 15 11 41 15 100 29
Intrauterine balloon 32 10 14 28 5 19 23
Intrauterine packing 30 15 22 22 5 22 21
Intra-abdominal packing 6 30 0 3 0 4 7
Uterine artery ligation 6 5 8 3 5 4 5
Uterine artery embolization 29 10 19 19 5 22 22
Laparotomy 36 70 51 63 15 13 38
Re-laparotomy 8 30 5 0 0 6 9
B-Lynch suture 5 0 3 3 10 0 2
Hysterectomy 27 70 38 66 5 9 25
aAbnormally invasive placenta
bIncluded only removal of the placenta (or placental remnant) not performed during cesarean section
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in France found that uterine atony remained the main
cause of PPH regardless of mode of birth [12, 27]. The
higher percentage of laparotomies performed after
cesarean section is consistent with previous findings
from the LEMMoN-cohort that the risk of postpartum
laparotomy was more than 16 times higher in women
who delivered by cesarean section compared to those
who delivered vaginally [29].
As a last resort to arrest heavy bleeding, a quarter of
all women underwent hysterectomy. This percentage is
considerably lower than reported by Green et al. for the
UK, where the overall rate of hysterectomy was 45%. A
possible explanation for this difference could be the
lower rates of previous cesarean deliveries; 66/327 (20%)
in our study versus 73/181 (40%) in the [12]. Two stud-
ies showed that the risk of peripartum hysterectomy
increased with the number of previous cesarean deliver-
ies [30, 31]. Another contributing factor could be the
higher rate of embolization in our study, 72/327 (22%)
versus 29/181 (16%) in the UK, and thereby preventing
the need for hysterectomy. Furthermore, uterine rup-
ture or an abnormally invasive placenta had the highest
rates of hysterectomy compared to other causes. This is
coherent with the recommendation of the Dutch
Society of Obstetrics and Gynaecology guideline that
states that hysterectomy should not be postponed if
the cause of hemorrhage is related to a placenta
accreta or ruptured uterus [10].
The maternal mortality rate of massive transfusion
due to PPH in our study was low with 0.84 deaths per
100.000 maternities. This is comparable with the mater-
nal mortality rate of PPH in the Netherlands reported by
Schutte et al. between 1993 and 2005 (0.7 deaths per
100.000 maternities) [32]. Nearly three-quarters of
women who received massive transfusion were admitted
to an ICU, and about one-third experienced morbidity.
This high rate of morbidity is consistent with other
studies [12, 26]. The rate of morbidity may be higher in
low-income settings where not all treatment modalities
are available or for Jehovah’s witnesses who refuse blood
products [3, 15, 33].
A key strength is that our results were based on a
nationwide cohort compromising all hospitals in the
Netherlands with a maternity unit. Considering that
PPH cases requiring massive transfusion must have
been managed in one of these units, our results are
population-based. Furthermore, our results are dir-
ectly comparable to those of Green et al. who used
the same definition for massive transfusion in their
analysis of a UK cohort [12].
However, number of red blood cell concentrates as
definition for massive transfusion remains an indicator
with shortcomings as well, since it can be influenced by
other factors, such as obstetrician’s decision-making. We
also acknowledge that our data are from 2004 to 2006
and may not reflect the current situation. Since the
incidence of PPH increased significantly throughout
the years in many countries, but the incidence of ob-
stetric blood transfusion in the Netherlands decreased
[3], it is possible that the incidence of massive trans-
fusion due to PPH may have reduced in recent years,
but this is subject of further assessment. There may
have been inclusion bias, since identification and
management of cases may differ between obstetricians
and hospitals. Underreporting is a concern, however,
we have previously observed that there is a negative
correlation between the rate of underreporting and
the number of red blood cell concentrates transfused
[34]. Therefore, we would expect a low rate of un-
derreporting. The considerable number of women
without a known Hb-level at discharge is likely due
to missing data, as a result of the design of the
LEMMoN-database that did not specifically include
Hb-level at discharge.
Nevertheless, this study makes clear that the incidence
of PPH requiring massive transfusion was high in the
Netherlands at that time compared to other countries
and further research of contemporary obstetric cohorts
is needed to allow for more up to date international
comparisons of rates of transfusion and hemorrhage-
related morbidity. Networks such as the International
Network of Obstetric Surveillance Systems (INOSS)
could facilitate such studies [35].
Conclusions
This study adds to the understanding of causes, ma-
nagement and outcomes of women with postpartum
hemorrhage requiring massive transfusion and our results
show that massive transfusion due to PPH is complicated
by high rates of morbidity and a considerable risk of hyster-
ectomy. The incidence of massive transfusion due to PPH
appears higher in the Netherlands compared to the UK and
the US. Increased vigilance for women at risk or in early
stages of postpartum hemorrhage in the Netherlands is
needed, while avoiding unnecessary over-transfusion. Spe-
cific reasons for the higher incidence will have to be studied
in order to improve care accordingly. Our results show the
importance of population-wide studies of severe maternal
outcome in general, and those comparing rates of transfu-
sion and outcomes for women with severe postpartum
hemorrhage in particular.
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